Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.63 |
| ▸ | MITF | O75030 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.63 |
| ▸ | TUBB | P07437 | 2/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319271 | 0.86 | MEN1 (0.73) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4333695 | 0.85 | HSD17B10 (0.76) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4322225 | 0.85 | HTT (0.80) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4320586 | 0.80 | MEN1 (0.82) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4322249 | 0.79 | MEN1 (0.82) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4320678 | 0.78 | HSD17B10 (0.71) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4319229 | 0.77 | MEN1 (1.00) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4327784 | 0.76 | MEN1 (0.71) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4327744 | 0.74 | ALDH1A1 (0.70) | HSD17B10ALDH1A1MEN1KMT2APKM | |
| SCHEMBL4327653 | 0.73 | MYB (0.75) | HSD17B10ALDH1A1MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | claimed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | claimed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | claimed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6906203-B1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP5 | HSD17B10 493/4885ALDH1A1 2306/4885MEN1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.